¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
3/16 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2024-03-13
Á¶È¸¼ö
72


¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ±è¼öÁöÀÔ´Ï´Ù.

Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº 2022³â Science Translational Medicine ¿¡ ÃâÆǵÈ
"An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice" ÀÔ´Ï´Ù.

ÀÌ ¿¬±¸´Â ´Ù¾çÇÑ aluminum hydroxide ¿Í PRR (pattern recognition receptor) agonist ¸¦ adjuvant ·Î »ç¿ëÇÏ¿© SARS-CoV-2 RBD ¿Í ÇÔ²² subunit vaccine À» ¸¸µé¾î ±× È¿°ú¸¦ ºñ±³ÇÑ ³í¹®À¸·Î, young adult mouse ¿Í aged mouse ¸¦ ºñ±³Çß½À´Ï´Ù.
aluminum hydroxide ¿Í CpG ¸¦ ÇÔ²² ÁØ formulation ¿¡¼­ µÎ ¿¬·É´ë ¸ðµÎ ÁßÈ­Ç×ü°¡°¡ ³ô°Ô ³ªÅ¸³µÀ¸¸ç challenge ½Ã¿¡µµ aged mouse ¿¡ º¸È£È¿°ú°¡ ÀÖÀ½À» È®ÀÎÇß½À´Ï´Ù.
À̸¦ È­ÀÌÀÚÀÇ  BNT162b2 mRNA ¹é½Å°ú ºñ±³ÇßÀ» ¶§¿¡µµ À¯»çÇÑ È¿°ú¸¦ º¸¿´À¸¸ç VOC ÀÎ B.1.351 (beta) variant ¿¡ ´ëÇؼ­µµ cross-immune response °¡ ÀϾ´Â °ÍÀ» È®ÀÎÇß½À´Ï´Ù.
ÀÌ adjuvant ´Â °¢ ¿¬·É´ëÀÇ ¸¶¿ì½º¿¡¼­ À¯»çÇÑ cytokine, chemokine »ý¼ºÀ» À¯µµÇß°í human PBMC »ùÇÃÀ» ÀÌ¿ëÇÑ ¿¬±¸¿¡¼­µµ ¸é¿ª ºÎ½ºÆÃÈ¿°ú¸¦ È®ÀÎÇß½À´Ï´Ù.


´Ù¾çÇÑ Adjuvant ¿Í ÇÔ²² Á¢Á¾µÇ´Â subunit vaccine ÀÇ È¿°ú¿Í adjuvant °£ ºñ±³, ¸ÞÄ¿´ÏÁòÀ» È®ÀÎÇÏ´Â ¿¬±¸¿¡ ´ëÇÑ ½ÇÇèµðÀÚÀΰú °ü·Ã ³»¿ë °øºÎ¸¦ À§ÇØ ¼±Á¤Çß½À´Ï´Ù. 


³í¹®»çÀÌÆ®: https://www.science.org/doi/10.1126/scitranslmed.abj5305 
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
3/16 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ´ÙÁ¤ÀÔ´Ï´Ù. Á¦°¡ À̹ø¿¡ ¼±Á¤ÇÑ ³í¹®Àº2021³â PNAS¿¡ÃâÆÇµÈ 'E2A-regulated epigenetic landscape promotes memory CD8 T cell differentiation'ÀÔ´Ï´Ù. À§ ³í¹®Àºsingle cell¼öÁØ¿¡¼­effector/memory CD8 T cell·ÎºÐÈ­ ÁßÀÇtranscriptional change¿¡ ´ëÇÏ¿© ¿¬±¸ÇÑ ³í¹®ÀÔ´Ï´Ù..
ÀÌÀü±Û
3/9 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä. À̹øÁÖ¹ßÇ¥ÀÚ¿µÁø ÀÔ´Ï´Ù. Á¦°¡¹ßÇ¥ÇÒ ³í¹®Àº 2024³â JACI ¿¡ ÃâÆÇµÈ " Blocking CD226 regulates type 2 innate lymphoid cell effector function and alleviates airway hyperreactivity" ÀÔ´Ï´Ù. Type 2 innate lymphoid cell(ILC2)´Â asthma ¹ß»ý½Ã ÁÖ¿äÇÑ ¿ªÇÒÀ» Çϱ⿡, ..